Lupin Launches Lotemax Generic

  Published 8 months ago

Lupin launches Loteprednol Etabonate Ophthalmic Suspension, a generic equivalent of Lotemax, targeting $55 million U.S. market.

  • Drug treats steroid-responsive eye inflammations and post-surgery swelling, matching Lotemax’s therapeutic efficacy.
  • Lotemax posted $55 million U.S. sales in May 2025, per IQVIA data; Lupin aims to capture share.
  • Mumbai-based Lupin distributes across 100+ markets, focusing on complex generics, APIs, and biotech solutions.

You might like these

Markets Steady Ahead of RBI Policy Decision

Amazon Shareholder Meeting: Proposals Rejected

India Telecom 2024-25: Subscriber & Revenue Trends

India's Long-Term Bonds Under Fire as Demand Wanes

Jio BlackRock Mutual Fund Approved

RateGain Launches Real-Time Analytics for Hotel Distribution

Birlasoft Shares Plunge on Downgrade

News that matters the most ⚡